To sign up for our free research reports and newsletters, visit http://BeaconEquityResearch.com. For more information on our research programs, please contact: Jeff Bishop at editor@beaconequityresearch.com
Chemokine Therapeutics Corp. (OTCBB: CHKT) Up 38.89% on Tuesday
Detailed quote: http://beaconequityresearch.com/CHKT
January 08, 2008 - Chemokine Therapeutics Receives Approval From FDA to Commence Phase II Study
Chemokine Therapeutics Corp. (the "Company") (TSX:CTI)(OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that it has received notice from the U.S. Food and Drug Administration (FDA) allowing the Company to begin a Phase II study in liver cancer with its lead drug candidate, CTCE-9908.
The Phase II trial will be a multi-centre, randomized, controlled, open label study assessing the efficacy and safety of CTCE-9908 administered at a dose of 5 mg/kg. The primary end point will be to determine the response rate of tumours in patients with liver cancer treated with CTCE-9908 following transarterial chemoembolization (TACE) (a therapy used for non-resectable liver cancer) compared with patients receiving TACE alone. The Company will follow patients to also determine progression free survival, overall survival, as well as various tumour and angiogenic factors.
"We are pleased the FDA has completed a review of our comprehensive regulatory filing allowing us to move forward with our planned Phase II clinical trial," said Walter Korz, Vice President of Drug Development. "This will be the Company's first study initiated under an FDA investigational new drug (IND) application with CTCE-9908."
iVoice, Inc. (OTCBB: IVOI) Up 15.38% on Tuesday
Detailed quote: http://beaconequityresearch.com/IVOI
January 08, 2008 - iVoice Enters into Technology Transfer Agreement with GlynnTech
iVoice, Inc. (OTC Bulletin Board: IVOI), announced today that it has entered into a Technology Transfer Agreement With GlynnTech to market its recently issued patent, "Methodology for Talking Consumer Products with Voice Instructions via Wireless Technology."
Jerry Mahoney, CEO of iVoice, Inc. said, "This invention enables users of new products to activate the speaking package of a new product, so there is no need to read instructions. For example, it provides for hands free, eyes free instructions while assembling new products, such as a bicycle, furniture, camera or other products."
iVoice, Inc., with GlynnTech's, Inc. assistance will develop a DVD of the patent's capabilities, GlynnTech, Inc., will assist in the preparation of the script, production and editing of the product DVD and receive a credits on the DVD. GlynnTech, Inc. will be obligated to solicit licensing opportunities and or acquisition of the patent.
Ken Glynn, president of GlynnTech Inc., has been involved in licensing of a variety of technologies for more than thirty years Besides representing such diverse, successful products as the SuperSoaker(R) Watergun, and the RotoWrench(R), Glynn has successfully licensed or sold more than thirty-four patents in the field of containers and packaging. He stated that this technology could eventually become a widespread method of using many consumer products.
Acro, Inc. (OTCBB: ACRI) Up 20.00% on Tuesday
Detailed quote: http://beaconequityresearch.com/ACRI
January 08, 2008 - Acro Inc. Extends Global Reach With the Appointment of New Distributors in UK, North America and APAC
In a move to further enhance its global exposure and strengthen its presence in the European, North America and APAC markets, Acro, Inc. (OTC BB:ACRI), a leading provider of explosives detection solutions, announced today the appointment of new distribution partnerships: IEDS (UK), Segal/Tyler Associates (USA), SecurIntel Solutions (Canada and South East Asia). The alliances serve to broaden global marketing channels for Acro Inc. products, responding to the growing demand for portable and cost effective explosives detection solutions in the above territories.
"IEDS Ltd" (http://www.snifferdogtraining.co.uk) focuses on Sniffing Dogs training for offensive and defensive counter terrorist search, serves as an excellent complement to our existing group of partners," said Gadi Aner, CEO of Acro Inc. "Through this partnership, we aim to broaden our security solutions to a wider range of end users."
"We are proud to welcome Segal/Tyler Associates and SecurIntel Solutions to Acro's growing portfolio of distribution partners In North America. I believe all will serve as significant assets in the development of a highly efficient distribution system, ensuring that the requirements of customers using Acro products and applications will be promptly met by the high quality technical expertise and service offered by our local partners," Aner further stated.
Worldwide Manufacturing USA Inc. (OTCBB: WWMU) Up 19.85% on Tuesday
Detailed quote: http://beaconequityresearch.com/WWMU
January 08, 2008 - Company Plans to Enter Alternative Energy Space With Production of Photovoltaic Cells and Modules for Residential, Commercial, Industrial and Public Utility Applications
Worldwide Manufacturing USA Inc. (OTCBB: WWMU) announced today that it will manufacture photovoltaic cells and modules for residential, commercial, industrial and public utility applications. The company has filed to change its name to Worldwide Energy and Manufacturing USA, Inc. to reflect its move into the alternative energy sector.
CEO Jimmy Wang said, "This name change will better reflect the expansion of our business into energy-related products. Our extensive manufacturing capability in China will allow us to enter the solar module space with major price and quality competitive advantages in 2008. We intend to manufacture and distribute solar modules worldwide for commercial, residential, industrial and public utility applications."
The Company believes its entrance into the solar module space and the continued expansion of its product lines will generate revenues of approximately $35 million and net income of $2.35 million in 2008.
CytoGenix, Inc. (OTCBB: CYGX) Up 23.08% on Tuesday
Detailed quote: http://beaconequityresearch.com/CYGX
January 08, 2008 - CytoGenix Announces Notice of Allowance in the U.S. for Herpes Patent
CytoGenix, Inc. (OTCBB:CYGX) announced today it has received a Notice of Allowance for a patent on its Herpes composition from the United States Patent and Trademark Office. The allowed patent entitled, "Treatment of HSV-Related Pathologies Using ssDNA," claims both the composition of matter utilizing the Company's single stranded DNA (ssDNA) expression vector technology and methods of treatment utilizing the therapeutic compound.
While most pharmacological agents are employed to chemically signal cells to interrupt, reduce production or bind and regulate specific disease-causing proteins, this application of Cytogenix's novel ssDNA technology directs infected cell(s) to make a short nucleic acid sequence that specifically targets and impedes the activity of a Herpes virus protein needed for viral reproduction. The specificity of this application reduces the possibility of side effects and/or long-term effects and is a more direct approach to targeting the origin of disease rather than merely treating symptoms.
"Allowance of this patent is an important element in our efforts to commercialize our Herpes therapeutic product. With this milestone accomplished, the Company is concentrating its efforts to complete required testing necessary to meet FDA regulations for an Investigational New Drug ("IND") application leading to clinical trials of its anti-Herpes Simplivir(TM) product candidate. The Company's decision to change its process from one using bacteria-based DNA production to its cell-free synDNA(TM) manufacturing technology has necessitated the process of resubmitting an IND for its Herpes therapeutic product. With necessary funding, the Company will move as quickly as possible towards the completion of this process", stated Malcolm Skolnick, CytoGenix President and Chief Executive Officer. "We remain confident that our Simplivir product will receive an IND that will allow us to proceed with clinical trials and ultimately to commercialization of this therapeutic."
Dr. Cindee Ewell, CytoGenix patent counsel, indicated, "Grant of this patent in the United States provides a major step forward in validating the use of our ssDNA expression technology in DNA-based therapeutics and should provide support for allowance of other Company patent applications utilizing similar technology."
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN THIS DOCUMENT. ALL INFORMATION PROVIDED HERE IS MERELY INFORMATIONAL AND IS NOT INTENDED TO BE A RECOMMENDATION TO BUY OR SELL ANY SECURITY. YOU SHOULD CONSULT A LICENSED INVESTMENT PROFESSIONAL BEFORE MAKING ANY INVESTMENT DECISION. All material herein has been prepared by us based upon information believed to be reliable. The information contained herein is not guaranteed by us to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not always approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. We are not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed or mentioned herein. Beacon Equity Research has been compensated a total of six thousand dollars by Worldwide Manufacturing for a limited participation in its research program. It is the policy of Beacon Research and its affiliates to sell any stock received for services, which may cause the stock price to become depressed. Our affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. We may sell shares for less than the target price given in this opinion, or at any time following the issuance of this announcement. We will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Beacon Research and its owners undertake no obligation to update such statements.
